Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Jiangsu Synthgene Biotechnology is a leading Chinese biotech specializing in upstream raw materials for life science applications, including cGMP-grade nucleotides, modified NTPs, cap analogs for mRNA manufacturing, phosphoramidites for oligonucleotide synthesis, diagnostic antigens/antibodies, and related analytical services. The company has robust R&D capabilities with over 200 employees (60% in R&D), ISO9001 certification supporting cGMP production standards, Drug Master Files filed with the FDA for GMP products, and serves both medical/clinical and consumer health markets globally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Jiangsu Synthgene Biotechnology.